The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Xtandi (enzalutamide) plus ADT significantly slows disease progression vs darolutamide plus ADT in patients with mHSPC, according to a matching-adjusted indirect comparison analysis published in Future Oncology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
ClinicalTrials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 
By Peter Nelson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account